OncoMatch/Clinical Trials/NCT05992584
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Is NCT05992584 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lenvatinib, sintilimab plus SIRT for hepatocellular carcinoma.
Treatment: Lenvatinib, sintilimab plus SIRT — This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
Unresectable HCC (BCLC stage B/C)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who previously received hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: transarterial chemoembolization
transarterial chemoembolization (TACE)
Cannot have received: transarterial embolization
transarterial embolization (TAE)
Cannot have received: radiotherapy
radiotherapy
Cannot have received: systemic therapy
systemic therapy
Cannot have received: immunotherapy
immunotherapy for HCC
Lab requirements
Blood counts
Peripheral blood white blood cell count <3×10^9/L, platelet count <50×10^9/L, prolongation of prothrombin time ≥ 4 seconds
Liver function
Child-Pugh score 5-7
Child-Pugh score 5-7; Peripheral blood white blood cell count <3×10^9/L, platelet count <50×10^9/L; Prolongation of prothrombin time ≥ 4 seconds; Severe organ dysfunction (heart, lungs, kidneys)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05992584 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE B or BCLC STAGE C is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages